As of Jun 29, 2018 Zosano Pharma Corporation (NASDAQ:ZSAN) Sellers Decreased Their Shorts By 43.02%

June 29, 2018 - By Alice Reed

It was registered a decrease on Zosano Pharma Corporation (NASDAQ:ZSAN)’s shorted shares with 43.02%. FINRA announced shorted shares of ZSAN’s total 924,200 shares. That’s 43.02% down from 1.62M shares. 2 days will cost ZSAN with 523,600 average volume to restore its former position. 2.89% is Zosano Pharma Corporation float short.

ZSAN is touching $4.06 during the last trading session, after increased 2.01%.Zosano Pharma Corporation has volume of 185,578 shares. Since June 29, 2017 ZSAN has declined 85.30% and is downtrending. The stock underperformed the S&P500 by 97.87%.

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients.The firm is valued at $48.61 million. The Company’s lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.Currently it has negative earnings.

For more Zosano Pharma Corporation (NASDAQ:ZSAN) news announced briefly go to: Streetinsider.com, Benzinga.com, Benzinga.com, Streetinsider.com or Streetinsider.com. The titles are as follows: “After-Hours Stock Movers 06/27: (EDGE) (ZSAN) (MSG) Higher; (PIR) (BBBY) (XON) Lower (more…)” announced on June 27, 2018, “5 Stocks Moving In Wednesday’s After-Hours Session” on June 27, 2018, “40 Stocks Moving In Thursday’s Mid-Day Session” with a publish date: June 28, 2018, “UPDATE: BTIG Starts Zosano Pharma (ZSAN) at Buy” and the last “Pre-Open Movers 06/28: (DRRX) (ZSAN) (CAVM) Higher; (ASNS) (PIR) (WBA) Lower (more…)” with publication date: June 28, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: